Tandem Diabetes Care Inc (FRA:TD5A)
€ 46.5 -0.61 (-1.29%) Market Cap: 3.09 Bil Enterprise Value: 3.10 Bil PE Ratio: 0 PB Ratio: 13.74 GF Score: 77/100

Tandem Diabetes Care Inc at Nasdaq Virtual Investor Conference Transcript

Dec 04, 2020 / 05:30PM GMT
Release Date Price: €78.8 (+1.53%)
Dylan James
Nasdaq, Inc. - Assistant VP of Listing Services

Good morning, everyone. I'm Dylan James, Vice President of the Western region here at Nasdaq.

Pleased to welcome the team from Tandem Diabetes this morning. So joining us is John Sheridan, President and CEO of the business; and joining John is Leigh Vosseller, CFO. (Operator Instructions)

And so without any further ado, John, I'm going to go ahead and pass it over to you. Excited to hear the presentation this morning. And thanks very much for joining us.

John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director

Absolutely. Thank you, Dylan. And thanks to Nasdaq for having us. It's been a great conference so far.

Well, I just want to start off by saying that Tandem has had a very strong third quarter. We had record sales. We had 30% -- or 31% year-over-year growth, and it turns out that our domestic growth was 25% quarter-over-quarter. We saw the strength really in Control-IQ. The product has just been amazing. We also had the benefit of a full quarter

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot